Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
China
· Delayed Price · Currency is CNY 49.90
-0.85 (-1.67%)
At close: Mar 9, 2026
SHA:688192 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 801.14 | 359.9 | 91.29 | - | 10.29 | Upgrade
|
| Revenue | 801.14 | 359.9 | 91.29 | - | 10.29 | Upgrade
|
| Revenue Growth (YoY) | 122.60% | 294.25% | - | - | -62.95% | Upgrade
|
| Cost of Revenue | - | 11.84 | 7.66 | 3.65 | 12.93 | Upgrade
|
| Gross Profit | 801.14 | 348.06 | 83.63 | -3.65 | -2.65 | Upgrade
|
| Selling, General & Admin | - | 598.78 | 437.55 | 128.44 | 87.95 | Upgrade
|
| Research & Development | - | 721.16 | 801.15 | 660.87 | 583.67 | Upgrade
|
| Other Operating Expenses | 1,567 | -2.1 | -0.27 | -0.39 | 0.1 | Upgrade
|
| Operating Expenses | 1,567 | 1,318 | 1,239 | 788.9 | 671.73 | Upgrade
|
| Operating Income | -766.36 | -969.66 | -1,155 | -792.55 | -674.37 | Upgrade
|
| Interest Expense | - | -22.75 | -7.57 | -4.34 | -3.07 | Upgrade
|
| Interest & Investment Income | - | 2.24 | 3.64 | 2.53 | 3.65 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -2.45 | -1.45 | 10.1 | -6.45 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.03 | -0.07 | -0.04 | -0.03 | -0.08 | Upgrade
|
| EBT Excluding Unusual Items | -766.39 | -992.69 | -1,161 | -784.3 | -680.32 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 14.45 | 22.52 | 42.16 | 0.97 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | -0.01 | 0.02 | - | Upgrade
|
| Other Unusual Items | - | 38.59 | 30.5 | 6.39 | 9.47 | Upgrade
|
| Pretax Income | -766.39 | -939.65 | -1,108 | -735.74 | -669.88 | Upgrade
|
| Income Tax Expense | -3.08 | 0 | 0.1 | 0.26 | - | Upgrade
|
| Earnings From Continuing Operations | -763.31 | -939.66 | -1,108 | -736 | -669.88 | Upgrade
|
| Minority Interest in Earnings | - | 93.7 | - | - | - | Upgrade
|
| Net Income | -763.31 | -845.96 | -1,108 | -736 | -669.88 | Upgrade
|
| Net Income to Common | -763.31 | -845.96 | -1,108 | -736 | -669.88 | Upgrade
|
| Shares Outstanding (Basic) | 446 | 415 | 407 | 404 | 360 | Upgrade
|
| Shares Outstanding (Diluted) | 446 | 415 | 407 | 404 | 360 | Upgrade
|
| Shares Change (YoY) | 7.64% | 1.83% | 0.70% | 12.29% | 0.07% | Upgrade
|
| EPS (Basic) | -1.71 | -2.04 | -2.72 | -1.82 | -1.86 | Upgrade
|
| EPS (Diluted) | -1.71 | -2.04 | -2.72 | -1.82 | -1.86 | Upgrade
|
| Free Cash Flow | - | -788.1 | -1,000 | -677.15 | -501.26 | Upgrade
|
| Free Cash Flow Per Share | - | -1.90 | -2.46 | -1.67 | -1.39 | Upgrade
|
| Gross Margin | 100.00% | 96.71% | 91.61% | - | -25.72% | Upgrade
|
| Operating Margin | -95.66% | -269.43% | -1265.43% | - | -6556.55% | Upgrade
|
| Profit Margin | -95.28% | -235.05% | -1213.42% | - | -6512.85% | Upgrade
|
| Free Cash Flow Margin | - | -218.98% | -1095.44% | - | -4873.51% | Upgrade
|
| EBITDA | -726.78 | -930.08 | -1,114 | -753.85 | -636.97 | Upgrade
|
| EBITDA Margin | -90.72% | -258.43% | - | - | - | Upgrade
|
| D&A For EBITDA | 39.58 | 39.58 | 40.94 | 38.7 | 37.4 | Upgrade
|
| EBIT | -766.36 | -969.66 | -1,155 | -792.55 | -674.37 | Upgrade
|
| EBIT Margin | -95.66% | -269.43% | - | - | - | Upgrade
|
| Revenue as Reported | - | 359.9 | 91.29 | - | 10.29 | Upgrade
|
| Advertising Expenses | - | - | - | 1.94 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.